Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only. Document issued on: January 7, 2014

You should submit comments and suggestions regarding this draft document within 120 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <u>http://www.regulations.gov</u>. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this document, contact Patricia Bernhardt at <u>patricia.bernhardt@fda.hhs.gov</u>, or at 301-796-6136.



U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Office of In Vitro Diagnostic Device Evaluation and Radiological Health Division of Chemistry and Toxicology Devices

Preface

Additional Copies

Additional copies are available from the Internet. You may also send an e-mail request to <u>dsmica@fda.hhs.gov</u> to receive an electronic copy of the guidance or send a fax request to 301-847-8149 to receive a hard copy. Please use the document number 1756 to identify the guidance you are requesting.

Contains Nonbinding Recommendations Draft - Not for Implementation Table of Contents

I. I	NTRODUCTION	4
II.	BACKGROUND	4
III.	SCOPE	2
IV. CAR	REDUCING THE RISK OF BLOODBORNE PATHOGEN TRANSMISSION IN DIABET E 3	ES
A.	VALIDATED CLEANING AND DISINFECTION PROCEDURES	4
B.	DEMONSTRATION THAT THE DEVICE IS ROBUST TO CLEANING AND DISINFECTION PROCEDURES	
V.	DEVICE DESCRIPTION	6
VI.	PERFORMANCE EVALUATION AND CRITERIA FOR SMBG DEVICES	7
A.	PRECISION EVALUATION STUDY	7
В.	LINEARITY EVALUATION STUDY	9
C.	METHOD COMPARISON/USER EVALUATION	9
1	. General Study Design:	9
2	2. Data Analyses:	12
D.	INTERFERENCE EVALUATION	14
1	I. Endogenous/Exogenous Substances	
2	2. Hematocrit	17
E.	FLEX STUDIES	
1	I. Test Strip Stability Testing	
2	P. Temperature and Humidity Effects on SMBG Device	
Ĵ	3. Altitude Effects	
4	1. Short Sample Detection	23
5	5. Sample Perturbation Study	
Ć	6. Intermittent Sampling	
	7. Testing with Used Test Strips	
F. C	CALIBRATION AND EXTERNAL CONTROL MATERIALS	24
VII.	TEST STRIP LOT RELEASE CRITERIA	25
VIII.	SOFTWARE	26
IX.	LABELING	26
APPI	ENDIX 1. POTENTIAL SOURCES OF ERROR TO CONSIDER FOR SMBG DEVICES	34
APPI	ENDIX 2. SPECIAL 510(K)S AND SMBG DEVICES	37

Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use:

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I I. Introduction

2 3

4

5

6

7 8 This draft guidance document describes studies and criteria that FDA recommends be used when submitting premarket notifications (510(k)s) for self-monitoring blood glucose test systems (SMBGs) which are for over-the-counter (OTC) use by lay-persons. When finalized, FDA intends for this document to guide manufacturers in conducting appropriate performance studies and preparing premarket notifications for these device types.

9 This guidance is not meant to address blood glucose monitoring test systems which are
10 intended for prescription point-of-care use (e.g., hospitals, physician offices, long term care
11 facilities, etc.). FDA is issuing another draft guidance entitled "Blood Glucose Monitoring
12 Test Systems for Prescription Point-of-Care Use" to address those device types.

FDA's guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidances describe the Agency's current thinking on a topic and
should be viewed only as recommendations, unless specific regulatory or statutory
requirements are cited. The use of the word *should* in Agency guidances means that
something is suggested or recommended, but not required.

20 II. Background

Portable blood glucose monitoring systems (also called glucose meters) that measure blood 22

glucose concentrations are used by millions of people with diabetes every day. These devices 23

- are used by patients in a variety of settings including in their homes, at work, and in schools. 24
- 25

Historically, the FDA has not recommended different types of information in premarket 26 submissions (510(k)s) for blood glucose monitoring systems used by medical professionals as 27 compared to OTC devices intended for use by lay users. However, it has become 28 increasingly clear that these different use settings create distinct intended use populations 29 with unique characteristics and device design requirements. For example, medical 30 professionals are generally more proficient at performing testing and at running appropriate 31 controls, and they typically have a better understanding of test limitations as compared to lay-32 persons. Further, the term "lay-person" encompasses a group of individuals with wide ranges 33 in age, dexterity, vision, training received on performing testing, and other factors that can be 34 35 critical in the patient's ability to accurately use the device and interpret test results. 36 SMBG devices and the associated test strips used by lay-persons are also more likely to 37 undergo more varied storage and handling conditions compared to devices used in 38 professional settings. As such, these devices should be designed to be more robust and 39 40 reliable to accommodate actual use conditions. 41 In order to distinguish between prescription use blood glucose meters, which are intended for 42 use in point-of-care professional healthcare settings, and those intended for OTC self-43 monitoring by lay-persons, the Agency is issuing two separate draft guidances for (i) 44 45 prescription use blood glucose meters, for use in point-of-care professional healthcare settings, and (ii) SMBG devices intended for OTC self-monitoring by lay-persons. The FDA 46 believes that in making this distinction, SMBG devices can be better designed to meet the 47 needs of their intended use populations, thereby ensuring greater safety and efficacy. 48 49 In recent years, concerns have been raised citing infection control issues related to glucose 50 meters and the lancet device. According to the Centers for Medicare and Medicaid Services 51 (CMS) and the Centers for Disease Control and Prevention (CDC), blood glucose monitoring 52 devices (meters and lancing devices) can transmit bloodborne pathogens if these devices are 53 54 contaminated with blood specimens and are shared between users without effective cleaning, disinfecting and appropriate infection control measures. Though SMBG devices are intended 55 for home use, they should also be designed to withstand appropriate cleaning and disinfection 56 procedures over the life of these devices. These disinfection procedures should be properly 57 validated (see Section IV below) for this type of device and appropriate instructions provided 58 for the user. Validation methods should take into account the way in which the device is 59 used, e.g., by lay users at home (or in other non-professional settings). 60 61

III. Scope 62

63

This draft guidance document is limited to SMBGs, which are regulated under 21 CFR 64

862.1345, Glucose Test System. The product code NBW applies to SMBGs. 65

66 This document is **not** meant to address the following types of devices: 67 • Blood glucose monitoring test systems intended for use in prescription point-of-care 68 settings (e.g., hospitals, physician offices, long term care facilities, etc.) 69 • Devices used to screen and diagnose diabetes (such as clinical chemistry analyzers or 70 semi-quantitative strips). 71 • Implanted or continuous glucose sensors. 72 • Non-invasive glucose measurement devices, (i.e., devices that do not require removal 73 74 of a blood sample from a fingerstick or other anatomical site). • Devices for measurement of blood glucose in neonates. 75 76 The device types addressed in this document typically use capillary whole blood from 77 78 fingersticks or alternative anatomical sites. This device is not intended for use in healthcare 79 or assisted-use settings such as hospitals, physician's offices, or long-term care facilities because it has not been determined to be safe and effective for use in these settings, including 80 for routine assisted testing or as part of glycemic control procedures. Use of this device on 81 multiple patients may lead to transmission of Human Immunodeficiency Virus (HIV), 82 83 Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or other bloodborne pathogens. 84 We recommend that you contact the Division of Chemistry and Toxicology Devices in the 85 86 Office of In Vitro Diagnostics and Radiological Health if you have questions regarding 87 alternate intended uses of your device. 88

IV. Reducing the Risk of Bloodborne Pathogen Transmission in Diabetes Care

91

Because SMBG devices use blood specimens for glucose measurement, their design and 92 instructions for use are very important factors in reducing the risk of bloodborne pathogen 93 94 transmission during use. According to the Centers for Medicare and Medicaid Services (CMS) and the Centers for Disease Control and Prevention (CDC), blood glucose monitoring 95 devices, as well as blood lancet devices, can transmit bloodborne pathogens such as viral 96 hepatitis if these devices are contaminated with blood specimens and are shared between 97 98 users without effective cleaning and disinfection. You should address the following 99 considerations for device design and labeling: 100 All SMBG devices should be intended for single patient use. The intended use 101 • should clearly state that the SMBG device is intended for use by lay users and should 102 only be used for a single user. 103

- Meters should be designed such that all external materials can be cleaned (removal of organic soil) and disinfected (microbicidal process).
- All external surfaces of the meter, including seams and test strip port, should be designed for both ease of use and ease of cleaning and disinfection.

- You should develop an effective disinfection method that can be easily employed by lay users at home. You should provide the validated cleaning and disinfecting procedures for your SMBG device in your submission as well as in the labeling.
 Cleaning and disinfection are different processes and need separate validation procedures and specifications. See Sections IV.A and B. below for details on the recommended cleaning and disinfecting validation studies.
- You should validate the use of any disinfectant you recommend for use with your device, as described in more detail below. We recommend you consult the Environmental Protection Agency's (EPA) list of disinfectants that are registered for use against infectious bacteria and viruses1 when choosing disinfectants to validate for use with your device.
- You should clearly warn users that lancing devices are for single-patient use only and should NEVER be shared.
- Labeling concerning safe device use can reduce the risk of user error; therefore,
 instructions for cleaning and disinfection should be clear and detailed. Labeling for
 all test system components should incorporate the same proprietary device name
 (ABC blood glucose test system, ABC blood glucose meter, ABC blood glucose test
 strips, etc.). See Section IX, Labeling below for detailed labeling recommendations.
- Validation of cleaning and disinfection procedures involves both validation that the cleaning
 and disinfection products are effective against the primary viruses of concern (HIV, Hepatitis
 B, Hepatitis C) and validation that the cleaning and disinfection procedures do not deteriorate
 the device or alter device performance. FDA recommendations for such validation are
 outlined in the following sub-sections.
- 132

133 A. Validated cleaning and disinfection procedures

You should select cleaning and disinfection products that do not result in physical 134 deterioration of the device overall, or any device component, such as the housing, touch 135 pad, or buttons. You should make note of these physical indicators during your 136 137 validation study and provide this information in your 510(k). The disinfectant product you choose should be effective against HIV, Hepatitis C, and Hepatitis B viruses. 138 Outbreak episodes associated with glucose monitors have been primarily due to 139 transmission of Hepatitis B viruses. Please note that 70% ethanol solutions are not 140 141 effective against viral bloodborne pathogens, and the use of 10% bleach solutions may lead to physical degradation of your device. 142 143

To demonstrate that your disinfection protocol is effective against Hepatitis B virus you should perform disinfection efficacy studies to demonstrate that your procedure is effective with the external meter materials. Studies have demonstrated that viruses can remain infective for different time periods, depending on the surface. Viral survival may increase or decrease with the number of microbes present on a surface. Increasing

¹. Selected EPA-registered Disinfectants<u>http://www.epa.gov/oppad001/chemregindex.htm</u>

149	amounts of microbes can protect viruses from disinfection, but damaging effe	cts may also
150	result from microbial proteases and fungal enzymes. Factors that influence su	ırvival on
151	surfaces include fomite properties, initial viral titer, virus strain, temperature,	humidity
152	and suspending media. The simplest disinfection method would be the use of	towelettes
153	pre-saturated with a selected disinfectant. Disinfection with a towelette will r	educe the
154	risk of liquid getting into the meter device, therefore minimizing the chance o	f affecting
155	the glucose meter reading. However, you should choose a disinfectant that is	effective
156	(against Hepatitis B Virus) and compatible with your specific device. In addi	
157	should choose a disinfection method that uses products that would be readily	
158	the home user.	
159		
160	We recommend you refer to the following standards:	
161	• ASTM standard E1053-97(Reapproved 2002), Standard Test Method	for Efficacy
162	of Virucidal Agents Intended for Inanimate Environmental Surfaces	lor Eniouey
162	or virueraal rigents interact for manimute Environmental Surfaces	
164	• ASTM standard E23620-09, Standard Practice for Evaluation of Pre-s	aturated or
165	Impregnated Towelettes for Hard Surface Disinfection.	aturated of
166	impregnated rewelettes for flatd burlace Disinfection.	
100		
167	B. Demonstration that the device is robust to cleaning and disinfect	t ion
168	procedures	
169	You should demonstrate through bench studies that your SMBG device is rob	ust to
170	cleaning and disinfection procedures after multiple cleaning and disinfection	
171	should describe in your submission the study design and results demonstrating	-
172	analytical performance of the blood glucose monitoring system is not impacte	
173	cleaning and disinfection procedures.	
174		
175	You should address the following in designing your study:	
176		
177	• You should choose worst case scenarios with regard to cleaning and d	isinfection
178	frequency and end user environment to determine the number of clean	
179	disinfection cycles that should be tested. For example, the number of	
180	clean and disinfect the meter should be representative of the cleaning a	-
181	disinfection that the meter will be exposed to in its use life (typically 3	
182	 We recommend using the same disinfectant product for both cleaning 	
183	disinfection. The effects of multiple products on the efficacy of the di	
184	products are not well understood.	Shireetant
185	 You should demonstrate that the test strip port and all other openings and all other openings. 	are able to
185	withstand your recommended cleaning and disinfection procedures. T	
180	port and material seams are highly susceptible to blood contamination	-
187	is important to be able to clean and disinfect these portions of your me	
188		
	reduce the risk of bloodborne pathogen transmission.	
190	• When you evaluate your device after the cleaning and disinfection phat should ansure that the precedure does not cloud the free/display of the	-
191	should ensure that the procedure does not cloud the face/display of the	
192	does not corrode or erode the plastic housing or buttons. You should	note all

 193 194 195 196 197 198 199 200 201 202 203 204 	 these physical indicators throughout your study and include these results in your submission. You should evaluate the performance of the meter to ensure that repeated cleaning and disinfection does not affect performance (accuracy). You should also demonstrate that lifetime cleaning and disinfection of any re-useable lancing devices packaged or recommended for use with your meter does not affect its performance or exterior materials. You should include infection control in your risk analysis studies and incorporate your validated cleaning and disinfecting procedures into your risk assessment. You should incorporate your labeling instructions for cleaning and disinfection in your user study (see Section VI-C, below) to determine the effectiveness and clarity of the instructions in your labeling for lay users.
204 205	instructions in your labeling for lay users.

V. **Device Description** 206

207

You should provide a general description of the SMBG device in your 510(k). Typically, 208 much of this information is also included in the User Manual; however, some of the 209 information is not appropriate for the intended user (e.g., highly technical explanations) and 210 should be included in the 510(k) only. You should provide the following in the 510(k): 211 212

General device description: 213

214 215

Physical components of the system (including diagrams where appropriate). •

- Manufacturer's performance specifications. 216 •
- 217 • Description and explanation of the test principle, including chemical reactions.
- Description of the format of results, including units of measure and whether results 218 are reported in whole blood or plasma equivalents². 219
- Description of the composition and levels of control material. 220 •
 - User maintenance needs (e.g., batteries). •
- Features of the device, such as data transmission capabilities or features designed to 222 enhance robustness, including ease of use. 223
- Features designed to minimize the risk of bloodborne pathogen transmission among 224 • 225 patients.
- Description of features controlled by the software: 227
- 228

231

226

221

229 • Displays and user messages: This includes how the system determines and displays the glucose concentration; messages or displays that appear while a user is taking a 230

measurement; and features such as how a user can retrieve past results from storage in

² Note that for SMBG devices intended for use in the U.S., plasma equivalent results should generally be reported.

the device. 232 233 234 • Error messages: This includes any error messages that the SMBG displays. Examples include displays or messages that the user sees when a strip is inserted 235 incorrectly or removed prematurely; too small a sample is applied to the test strip; or 236 damaged, incorrect or deteriorated strips are used. You should also describe the error 237 238 tolerance for user actions, such as these, that are inconsistent with device operation. 239 User prompts: You should describe prompts that the device provides to the user, • 240 expected user responses, and timing issues (e.g., how quickly does the user need to 241 respond, what happens if they respond after the allowed time). Examples of a user 242 243 prompt are messages to the user to insert the test strip into the meter, add blood sample to the test strip, calibrate the meter, or store a result in memory. 244 245 Alarms and other feedback: You should describe how the system responds to errors in 246 • user action, user inaction, or system status, e.g., low batteries or high ambient 247 temperature. This includes methods by which the system detects and alerts the user 248 when glucose levels are outside of the linear range of the system. Further, you should 249 explain any self-diagnostic routines that the system performs. 250 251 It is important that you identify the expected responses by the user to messages. This 252 253 includes whether and how the user should input information or press certain buttons to correctly set up the meter or to respond to a message. 254 255

VI. Performance Evaluation and Criteria for SMBG Devices

258

Sections A-F below indicate the types of device performance information that you should
 include in a 510(k) submission for a SMBG device.

261

In this section, the term "reference method" refers to a laboratory-based glucose measurement method that has been well-validated for precision and accuracy, and that is traceable to a higher order, e.g., internationally recognized, reference material and/or method. The traceability chain should include as few stages as possible to reduce bias. FDA's current thinking on the issues that should be addressed and the recommended study designs and device performance evaluations are discussed below in Sections A-F.

269 A. Precision Evaluation Study

You should evaluate both repeatability and intermediate precision for your SMBG. The
following sections outline FDA's current thinking on appropriate study design and
analyses to evaluate repeatability and intermediate precision for SMBG devices.

274 *Measurement Repeatability Evaluation:*

- In order to assess imprecision of the device across the claimed measuring range, you
- should evaluate samples containing the following five glucose concentration intervals
- 277 provided in the table below:
- 278 279

Table 1. Glucose Concentrations for Repeatability Evaluation

Interval	Glucose Concentration
	Range (mg/dL)
1	30-50
2	51-110
3	111-150
4	151-250
5	251-400

280 281

You should determine repeatability using venous blood samples. Altered venous blood 282 samples such as those that are spiked, diluted, or allowed to glycolyze in order to obtain 283 the appropriate glucose concentrations are acceptable to facilitate coverage of the entire 284 glucose concentration range using the concentration intervals outlined in Table 1. 285 286 However, you should clearly identify all altered samples (spiked, diluted, or glycolyzed) in all submitted data. A minimum of 500 test strips from at least 10 vials and 3 287 manufacturing lots should be used in the study. For each sample concentration, a 288 minimum of 10 meters should be used for these studies, with at least 10 measurements 289 taken by each meter (i.e., 100 measurements per concentration). These tests strips should 290 be taken from the same vial and/or package for each meter. 291

292

We recommend you present the results as the mean value of the 10 measurements per 293 meter with the corresponding standard deviation (SD) and percent coefficient of variation 294 (CV). For each glucose concentration range in Table 1, you should also provide the mean 295 value, standard deviation (with 95% confidence intervals) and percent CV for data 296 combined over all meters. You should describe the statistical procedures used in the 297 298 analysis. You should also include a summary of any identified outliers that were excluded from statistical analysis, the method of outlier identification and the results of 299 these outlier investigations. 300

- 301
- 302 *Intermediate Precision Evaluation:*

Intermediate precision measurement studies are designed to measure imprecision under normal conditions of use by the intended user (i.e., measurement by individuals over multiple days, with the same meter, and reagent system lot). These studies should be performed with prepared materials, such as control materials for use with the SMBG device.

308

309 The total number of meters and individual users in these studies is at the discretion of the

- sponsor, however a minimum of 10 devices should be used for each concentration.
- Precision should be evaluated over a minimum of 10 days, taking at least 1 measurement

- per day of a sample from each glucose concentration interval listed in Table 1, for a minimum of 10 measurements per meter for each concentration (and 100 measurements per concentration). You should use a minimum of 500 test strips from a minimum of 10 vials or packages and 3 manufacturing lots. These tests strips should be taken from the same vial and/or package for each meter. The study should demonstrate acceptable precision for all lots, users and meters.
- 318

You should present data including the mean value of the measurements per meter with 319 the corresponding standard deviation (SD) and percent coefficient of variation (CV). For 320 each glucose concentration in Table 1 you should also present the mean value, standard 321 deviation (with 95% confidence intervals) and percent CV for data combined over all 322 meters. You should describe the statistical procedures you use. You should provide 323 results based on all data. If any outliers were excluded from any of your statistical 324 325 analyses, you should fully describe the method of outlier identification and the results of these outlier investigations. 326

327

328 B. Linearity Evaluation Study

You should evaluate the linearity of your device across the entire claimed measuring 329 range. We recommend that studies include an evaluation of at least 11 evenly spaced 330 concentrations tested and analyzed according to "Evaluation of the Linearity of 331 Quantitative Measurement Procedures: A Statistical Approach", CLSI document EP6-A. 332 Linearity studies should be performed using venous blood samples. Altered venous blood 333 samples such as those that are spiked, diluted, or glycolyzed are acceptable to facilitate 334 coverage of the entire glucose concentration range. You should clearly identify all altered 335 samples (spiked, diluted, or glycolyzed) within the submitted data. 336

337

You should submit a detailed description of the study design, target concentrations, a list
of all data collected in this study, summary of the results and conclusions drawn from the
study, and a description of the statistical analysis used.

341

342 C. Method Comparison/User Evaluation

343 344

1. <u>General Study Design:</u>

We recommend that you design a single evaluation to assess both system accuracy in the hands of the intended users, as well as other aspects to support lay use, such as labeling assessment and usability. This type of design will more accurately reflect the device performance in the hands of the intended user, therefore providing a better estimate for total accuracy of the SMBG device.

- 350
- 351 FDA recognizes that most study evaluations performed for pre-market submissions occur
- in idealized conditions, thereby potentially overestimating the total accuracy of the
- 353 SMBG device, even when performed in the hands of the intended user. It is important to
- design your study to most accurately evaluate how the device will perform in the hands of

- the intended use population. Therefore, the study should be conducted under conditions
 that reflect the expected use of the device by the intended use population. These
 conditions should be consistent with the validated environmental conditions of the device
 (e.g., temperature, humidity, altitude etc.). You should fully describe the conditions of
 your study in your pre-market submission.
- 360

You should include at least 350 different subjects in your method comparison study.
Fresh capillary samples should be obtained with sufficient volume to be measured on
both the candidate device and the reference method. If you are planning to include claims
that your device can be used at alternative sites (e.g., forearm, palm, etc.), you should
obtain and evaluate 350 samples from each site.

366

For each claimed anatomical site the samples should adequately span the claimed 367 368 measuring range of the SMBG device. Though it may be difficult to obtain samples at the extreme ends of the measuring range, the study should contain at least 10 unaltered 369 samples with blood glucose concentrations < 80 mg/dL, and at least 10 unaltered samples 370 between 250 mg/dL glucose and the upper limit of the claimed measuring range of the 371 device. If these ranges are not covered after collecting samples from 350 subjects (for 372 373 each sample site), additional subjects should be enrolled until adequate sample concentrations are collected. Data from all subjects in the study should be submitted, and 374 375 no subjects should be excluded from the data analysis. 376

- The subjects you enroll in the method comparison/user study should accurately reflect the intended use population of the device. The study group should be comprised of both naïve and non-naïve SMBG users. At least 10% of the study participants should be naïve to SMBG devices. You should describe the inclusion and exclusion criteria for enrolling the study participants, as well as the demographic characteristics of the subjects that participated in the study.
- 383

Prior to testing, study subjects should be given the device labeling (instructions for use, 384 user manual etc...) that will be provided to the user with the device once on the market. 385 For purposes of the study these instructions for use should be written in English only: 386 translations into other languages should not be provided to these study participants. 387 Prior to the study, you should perform a readability assessment (in terms of grade level) 388 389 of the user manual, test strip insert, and control solution insert. For an over-the-counter product the reading level should be at an 8th grade level or less. We recommend using 390 the Flesch-Kincaid, SMOG, or equivalent computer program to assess the readability 391 grade level of the labeling. You should describe the assessment and results in your 392 submission. 393

394

The study subjects should obtain their own capillary sample and perform a blood glucose test using only the device labeling as instructions. No other training or prompting should be provided to the user, and they should not receive assistance from a study technician or healthcare provider to obtain the test result. Study subjects should be sequestered in such a way so they can not observe or be influenced by the testing technique of other study

- participants or technicians. Once the study participant has obtained their own result using
 the SMBG device, the technician should then obtain an additional capillary sample for
 testing on the reference method. Since the intended user population of SMBG devices is
 the lay-person, it is not necessary for the technician to obtain capillary results on the
 SMBG device for comparison to the reference value.
- 405

You should include a minimum of 3 test strip lots and a minimum of 10 test strip vials or
packages in the study. All test strips used in the study should have undergone typical
shipping and handling conditions from the site of manufacture to a U.S. user prior to
being used in the study. You should describe these shipping and handling conditions in
your premarket submission.

411

Hematocrit values should be determined and recorded for each of the study participants.
You should present individual hematocrit values in the 510(k) along with the meter
results.

415 Blood glucose test results are used by people with diabetes to make critical decisions 416 about their treatment; therefore, it is important that the results are accurate so that 417 nutritional and drug dosing errors are better avoided. In order to demonstrate that your 418 SMBG device is sufficiently accurate to be used safely by diabetic patients for this 419 420 purpose, you should demonstrate that 95% of all SMBG results in this study are within +/- 15% of the reference measurement across the entire claimed measuring range of the 421 device and that 99% of all SMBG results are within +/- 20% of the reference 422 423 measurement across the entire claimed measuring range of the device. You should include all results in the submission. If there are any SMBG test results that are $\geq 20\%$ 424 relative to the reference, you should provide a justification for why the errors occurred 425 and describe why the potential for that error does not render the device unsafe and 426 427 ineffective, even when extrapolated to the intended use setting (e.g., when billions of tests are performed). We will review the justification to determine whether the data suggests 428 that patients may be put at risk, or whether the sponsor's justification and proposed 429 mitigation would be adequate. 430

431

FDA understands that some SMBG devices may not be able to measure reliably within 432 15% of the reference method at very low concentrations. If this is the case, you may need 433 to raise the lower end of the claimed measuring range to the concentration where your 434 device is sufficiently accurate according to the above described criteria. We expect that 435 to meet the clinical needs of the user population, SMBG devices should minimally be 436 able to measure blood glucose accurately down to 50 mg/dL and up to 400 mg/dL. The 437 SMBG device should identify and provide an error code in situations where the measured 438 glucose falls outside of the device's stated measuring range. For example, meter XYZ 439 has a measuring range that can detect glucose concentrations down to 50 mg/dL; 440 therefore, blood samples with glucose concentrations below 50 mg/dL should provide an 441 appropriate error code (e.g., "LOW - Less than 50"). 442

444	Method comparison and user performance studies for SMBG systems include multiple
445	users and multiple blood glucose monitoring devices. Individual lancing devices should
446	be used for each subject. The protocol for these studies should include measures in place
447	to mitigate the risk of potentially transmitting disease between healthcare providers,
448	subjects and users (for example use of disposable gloves or other physical barriers). The
449	study protocol should also include details on how often and when gloves of the trained
450	health professionals should be changed between users. Refer to Section IV above
451	(Reducing the Risk of Bloodborne Pathogen Transmission in Diabetes Care) for
452	additional information regarding the validation of cleaning and disinfecting of SMBG
453	devices. You should describe these aspects of the protocol in your 510(k).
454	
455	You should also describe the following in your 510(k):
456	
457	• Study setting (i.e. description of the type of study location and operators used for
458	the study and a justification of how the selected study conditions simulate
459	intended use conditions).
460	• Type of study participants and the inclusion and exclusion criteria used to select
461	the participants.
462	• Patient demographics (age range, education level, native language, work
463	experience, disease state) and whether they are naïve SMBG device users or not.
464	• Details of procedures performed by lay users and study technicians.
465	• Instructions provided to users in the study. (Note: All instructions must be
466	provided to users in English only.)
467	• Type of sample collected (anatomical collection site(s)).
468	• Number of test strip lots, number of test strip vials, and number of meters used in
469	the study.
470	• Description of the shipping and handling conditions of the test strips prior to use
471	in the study.
472	• A user questionnaire should be provided for the study participants to fill out after
473	completing the study. A copy of the questionnaire and the results should be
474	provided in the submission.
475	-
476	2. Data Analyses:
477	You should present all data in the submission, including cases in which the meter
478	displays an error code, a 'High' or 'Low' message, or no result. All outliers that do not
479	conform to the minimum accuracy criteria should also be included. All such outlier
480	results should be investigated and explained when possible. To assist in this
481	investigation, you should collect information regarding patient medications, hematocrit
482	measurements, disease states during your study. You should include the following in
483	your description of the results:
484	
185	Regression analysis:

485 *Regression analysis:*

- You should present the difference between individual study subject results and the 486 reference value (or mean of the reference value, if multiple replicates are measured on the 487 reference method) by plotting the candidate SMBG device as the dependent variable and 488 the reference value as the independent variable. The plot should include the regression 489 line and line of identity, as well as the 95% and 99% confidence intervals. Your 490 summary of results should include the slope and v-intercept, calculated using suitable 491 492 regression analysis procedures, and the estimate of the deviation such as the standard error (Syx). You should describe all statistical methods used and clearly identify and 493 describe any outliers in the analysis. 494
- 496 *Tabular data presentation:*
- In addition to providing the results of regression analysis, you should also present results
 in the following tabular format for each sample matrix. In this table, X= the number of
 samples within the specified difference from the reference method, and Y= total number
 of samples.

502 **Table 2. Summary of data within specified mg/dL of the reference method:**

503 For glucose concentrations across the entire range:

Within +/- 5	Within +/- 7	Within +/- 10	Within +/- 15
mg/dL	mg/dL	mg/dL	mg/dL
X/Y (%)	X/Y (%)	X/Y (%)	X/Y (%)

504 505

495

501

506 Accuracy at Extreme Glucose Values

507 Because the user study may not provide a sufficient evaluation of the device performance 508 in the extreme upper and lower ends of the measuring range, you should perform 509 additional studies using blood samples altered to less than 80 mg/dL and greater than 250 510 mg/dL. These samples should mimic unaltered patient samples as closely as possible. 511 These additional studies should be performed separately from the above mentioned 512 method comparison/user performance evaluation (Section VI.C) and may be performed in 513 a laboratory setting (e.g., at the manufacturer's facility)

a laboratory setting (e.g., at the manufacturer's facility).

Capillary whole blood samples should be used for these studies. You should include a
minimum of 50 prepared samples containing glucose concentrations below 80 mg/dL and
So samples greater than 250 mg/dL. These samples should evenly cover the lower and
upper limits of the claimed measuring range. Samples may be altered by spiking or
allowing the samples to glycolyze in order to obtain the appropriate glucose
concentrations. Samples should be measured on both the SMBG device and the reference
method. You should analyze the data using the same methods described above for the
user evaluation studies. FDA will also apply the same review criteria.

- 522 523
- 524 Error Codes for Samples Outside the Measuring Range:
- 525 You should demonstrate in your premarket submission that your device provided the

appropriate error codes when glucose concentrations were out of the device's stated

527 measuring range.

528

529 D. Interference Evaluation

530 You should evaluate the effect of potentially interfering endogenous and exogenous 531 substances and conditions on device performance. This includes icterus, lipemia, and 532 varying hematocrit levels, as well as the effect of common medications.

- 533
- 534

540

1. Endogenous/Exogenous Substances

535 Study design:

536 You should perform interference testing using samples containing glucose concentrations 537 across the range of the device. Specifically, testing should be performed in samples with 538 glucose concentrations of 60 mg/dL, 120 mg/dL, and 250 mg/dL to evaluate clinically 539 relevant decision points.

You should evaluate each potentially interfering substance at clinically relevant 541 concentrations. You should test all substances at a minimum of two concentrations – the 542 concentration that is expected or the therapeutic concentration, and the concentration that 543 is the highest that could potentially be observed in a whole blood sample. For example, 544 acetaminophen should be tested at the expected therapeutic concentration 20 µg/mL and 545 also at the high, toxic concentration 200 µg/mL. Table 3 below lists our 546 recommendations on the substances and concentrations that should be tested for 547 interference. Table 4 below provides a sample format. 548

549 550

Table 3. List of Potential Interferents for SMBG Devices

Interferent	Therapeutic Level	High Toxic Concentration
Acetaminophen	20 µg/mL	200 μg/mL
Ascorbic acid	0.8 mg/dL	3 mg/dL
Bilirubin	1 mg/dL	25 mg/dL
Cholesterol	154 mg/dL	309 mg/dL
Creatinine	1 mg/dL	10 mg/dL
Dopamine	20 pg/mL	200 μg/mL
EDTA	0.1 mg/mL	2 mg/mL
Galactose	1 μg/mL	100 μg/mL
Gentisic acid	0.1 mg/mL	10 mg/mL
Glutathione	5 μmol/L	100 μmol/L
Hemoglobin	14 g/dL	20 g/dL
Heparin	0.5 IU/mL	5 IU/mL
Ibuprofen	10 µg/mL	500 μg/mL
L-Dopa	2 μg/mL	5 μg/mL
Maltose	1 mg/mL	100 mg/mL
Methyldopa	10 mg/L	10 g/L
Salicylate	100 µg/mL	500 μg/mL
Sodium	120 mEq/L	175 mEq/L
Tolbutamide	100 mg/L	1000 mg/L

Tolazamide	40 mg/L	400 mg/L
Triglycerides	100 mg/dL	500 mg/dL
Uric acid	5 mg/dL	10 mg/dL
Xylose	20 mg/dL	200 mg/dL
Sugar Alcohols [*]	0.03 mg/100mL	0.09 mg/100mL

*All common sugar alcohols should be tested including mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol
 and hydrogenated starch hydrolysates (HSH). Sponsors should determine appropriate levels to test for
 interference with SMBG devices based upon common concentrations of these substances in the blood of
 diabetic patients.

555

You should provide a reliable estimate of the interference predicted for individual 556 samples. To do this, we recommend the following method of measuring and calculating 557 interference: Each sample should be tested on the reference method in replicates 558 (minimum of 4). An average of reference measurements, for example, may give greater 559 confidence in the true glucose concentration of the sample. You should use at least 3 test 560 561 strip lots to evaluate interference. Each test sample should be tested on the new SMBG device in replicates of 30 (10 replicates per lot of test strips, for a total of 30 replicates per 562 sample). Each replicate should be compared to the average value obtained from the 563 reference method and a bias and % bias calculated. The % bias for each replicate should 564 be combined to produce an average % bias for the sample (with 95% confidence 565 intervals). 566

567

In the rare case where the substance being evaluated for interference with the new device also interferes with the reference method, a reference sample should also be created for each substance that contains the identical glucose concentration but solvent/vehicle in lieu of the potential interfering substance. The test sample can then be compared to the reference sample value as measured by the reference method. You should provide information demonstrating interference with the reference method for each substance in this category.

575

For SMBG devices intended for lay use, the degree of acceptable interference may vary 576 by substance tested. For example, a small interference at extremely high acetaminophen 577 concentrations may be able to be communicated through labeling because users are aware 578 that they have or have not taken that drug. Other potential risks, e.g., observed 579 interference from uric acid, may be more difficult to mitigate through labeling because 580 the user may be unaware of their condition or incapable of determining at home whether 581 they may be at risk. Therefore, you should report in the 510(k) the observed average 582 percent bias for each sample/substance tested and any observed trends. If interferences 583 are observed, then you should propose appropriate labeling to mitigate the risk of the 584 interference in the lay user population; the labeling language appropriate for the observed 585 interference will be discussed during the review of the submission. We do not 586 recommend that final labeling be printed prior to receiving FDA input during the review. 587 588

589 If significant interference is observed at one substance concentration but not the other, 590 you should perform additional analyses to determine the concentration at which 591 interference begins to occur. For example, if a bias of 12% is observed at 200 µg/mL

- dopamine and no significant bias is observed at dopamine concentrations of 20 pg/mL,
 additional testing should be performed to determine the lowest concentration between 20
 pg/mL and 200 µg/mL where interference is first observed. In the 510(k), you should
- 595 provide vour definition of "significant" interference for that substance.
- 596

The substances listed above in Table 3 represent known or reasonable potential 597 interferents for current glucose measurement technologies. As new drugs are developed 598 or new interfering substances are identified, you should evaluate them for potential 599 interference with your device. For example, if a new drug intended to treat cardiac 600 complications in diabetic patients is approved, you should conduct a robust evaluation to 601 determine whether the new drug interferes with your device. You should report to FDA if 602 significant new interferences are observed with any cleared glucose monitoring device 603 that is on the market. You should also evaluate new drugs/potential interferents when 604 new or significantly modified technology is introduced. 605

607 Data Analysis:

You should provide raw data sets as well as a summary table for all results in your
submission. Please note that the summary tables should be presented separately for each
test strip lot and glucose level tested. Table 4 below provides a sample format.

611

606

612Table 4. Recommended Summary Table Format:

613 Lot 1/Glucose Concentration (60 mg/dL)

614 *Potential Interferent: Acetaminophen*

Mean Glucose Value (YSI)	Interference Level	Mean Glucose (Meter)	Bias (mg/dL)	% Bias	Confidence Interval
60 mg/dL	20 µg/mL				
	100 µg/mL				
	200 µg/mL				

615


616 We recommend you also present data graphically for each individual test strip lot.


617 Graphs should describe the percent bias for all data points included in the study at

therapeutic, toxic and any intermediate levels. The graph should include the mean

glucose measurement obtained by the meter as well as the confidence intervals around the

- 620 bias. A sample graph is shown below:
- 621





Interferent Concentration

623 624

622

In your 510(k) you should include a detailed description of the study design, a list of all
data collected in this study, the summary tables and graphs indicated above and a
description of the conclusions drawn from the study.

628 629

2. <u>Hematocrit</u>

630 Study Design:

You should evaluate the effect of hematocrit on the performance of your system to assess 631 632 whether the device can be used safely in the intended use population across your claimed hematocrit range. The observed hematocrits may be very broad in the intended use 633 population for this type of device; the majority of intended users may reasonably be 634 expected to have hematocrit values between 20 and 60% hematocrit. Therefore, we 635 recommend 20-60% hematocrit as the claimed range for this type of device. If your 636 device is subject to significant interference from hematocrit within that range, you should 637 include limitation statements in your labeling cautioning against use when certain 638 physiological conditions are present or suspected (e.g., anemia, etc.). Because lay users 639 generally have no way to adequately determine their hematocrit status, devices that 640 641 cannot adequately measure glucose across the range of 30-55% hematocrit (which includes the greatest proportion of users) cannot be safely used to monitor blood glucose 642 and may not be determined to be substantially equivalent. 643

644

Because a reasonably sized method comparison study still may not include the full range 645 of hematocrit values expected in the intended use population, you should perform a 646 separate study to determine how much analytical error may be contributed by this 647 condition. You should evaluate hematocrit interference by measuring samples containing 648 various glucose concentrations in reconstituted blood. The samples should be prepared to 649 contain designated levels of hematocrit that span the claimed hematocrit range for the 650 device. The blood sample may be adjusted by spiking or allowing it to glycolyze to 651 obtain the desired glucose concentration. Specific percentages of hematocrit may be 652

achieved for each sample by manipulating the plasma to packed cell ratio following 653 centrifugation. Hematocrit levels tested should span the claimed range in 5% intervals. 654 For example, if your claimed hematocrit range is from 20-60%, you should test samples 655 at 20, 25, 30, 35, 40, 45, 50, 55, and 60 % hematocrit. The samples should also span the 656 claimed measuring range for blood glucose. Samples should include 5 different blood 657 glucose concentrations evenly spread and targeted to the following ranges: 30 - 50, 51 -658 110, 111 – 150, 151 – 250, and 251 – 400 mg/dL. 659 660

Each sample should be tested on the reference method in multiple replicates (a minimum 661 of 4). An average of reference measurements, for example, may give greater confidence 662 in the true glucose concentration of the sample. 663

664

A minimum of 3 test strip lots should be used to evaluate interference from hematocrit. 665 Each test sample should be tested on your new SMBG device in replicates of 30 (10 666 replicates per lot of test strips, for a total of 30 replicates per sample). Each replicate 667 should be compared to the average reference value for the sample and a bias and % bias 668 calculated. The percent bias for each replicate should be used to produce an average 669 percent bias for the sample (with 95% confidence intervals). 670

671

Because hematocrit interference is only one of the variables that will contribute to the 672 overall analytical error of the system, it is important that it represent only a portion of the 673 allowable error for the system. For this reason, bias observed in this study should be less 674 than 8% on average, and no individual value should be greater than 15% of the reference 675 676 method.

677

Data Analysis: 678

You should provide raw data sets as well as a summary of the hematocrit interference 679 study (see recommended format below). Please note that the summary tables should be 680 presented separately for each test strip lot and glucose level tested. 681

682


Table 5: Sample Format for Hematocrit Results: 683

Lot 1. Glucose Level 1 (30-50 mg/dL) 684

Mean Glucose Value (YSI)	Hct (%)	Mean Glucose Value (Meter)	Bias (mg/dL)	% Bias	# of Observations > +/- 15% Bias

685

You should also present the data graphically for each individual test strip lot. Graphs 686 should include percent bias for all data points included in the study. The graph should 687 include confidence intervals around the percent bias 688



689 690

You should submit a detailed description of the study design, a list of all data collected in
this study, the summary tables and graphs indicated above, and a summary of the
conclusions drawn from the study.

694

705

695 E. Flex Studies

There are typically fewer controls in place in OTC settings to mitigate risk. In addition, 696 the users are often untrained and may not know how to identify or address an incorrect 697 result. It is therefore assumed that the OTC devices are designed so the risk of an 698 erroneous result should be far less than with laboratory-based tests. You should therefore 699 demonstrate that your SMBG device design is robust (e.g., insensitive to environmental 700 and usage variation) and that all known sources of error are effectively controlled. In 701 general, flex studies should be used to demonstrate robust design while risk management 702 703 should be used to demonstrate identification and effective control of error sources, although the two are not mutually exclusive. 704

Most risk control measures should be fail-safe measures or failure alert mechanisms. 706 Examples of fail-safe mechanisms are lock-out functions to ensure that a test system does 707 not provide a result when test conditions are inappropriate, such when there is a 708 component malfunction or operator error. Other examples are measures within the system 709 710 to prevent operator error, such as guides or channels that prevent improper strip placement. We recommend that test system design incorporate fail-safe mechanisms 711 whenever it is technically practicable. If fail-safe mechanisms are not technically 712 practicable for some risks, failure alert mechanisms should be used. Failure alert 713 mechanisms notify the operator of any test system malfunction or problem. They may 714 715 include measures such as internal procedural controls or electronic controls. Devices with such mechanisms allow the operator to correct the error, or put the operator on notice that 716 the results will be unreliable due to the error. For example, in cases where the result 717

- exceeds the reportable range (e.g., extremely high or low glucose result) and the result is
 a critical value, the device should give a message such as "out of range high" or "out of
 range low."
- Flex studies, or studies that stress the operational limits of a test system should be used to validate the insensitivity of the test system to performance variation under stress conditions. Where appropriate, flex studies should also be used to verify and/or validate the effectiveness of control measures at operational limits. Flex studies are particularly important for OTC SMBG devices as these devices are intended for use by lay users and undergo a variety of environmental and user-associated conditions that could affect system performance.
- 729

721

In order to identify all relevant flex studies for your SMBG device, we recommend that 730 731 you conduct a systematic and comprehensive risk analysis that identifies all potential sources of error, including test system failures and operator errors, and identifies which of 732 these errors can lead to a risk of a hazardous situation. You should then identify control 733 measures, including fail-safe and failure alert mechanisms that will reduce risks for these 734 sources of error. When the control measures have been implemented, you should (1) 735 verify that each control measure has been properly implemented, and (2) verify and/or 736 validate the effectiveness of each control measure. When appropriate, flex studies should 737 738 be used to verify and/or validate the effectiveness of these control measures. 739

- Below we have identified several flex studies that we believe are important for you to perform in order to demonstrate adequate performance of OTC SMBG systems. At the same time, we continue to encourage you to perform risk analyses to determine whether your device includes any unique or new features that should be validated through flex studies.
- If your SMBG device does not perform adequately in flex studies, we recommend you
 either provide a justification, determined by means of thorough risk analysis, as to why
 adequate performance under that flex study is not required for safe effective use of the
 device or indicate an additional validated control mechanism implemented to assure safe
 and effective use of the device. FDA will review such justifications to determine whether
 the proposed mitigation strategies are adequate to protect patients.
- 752

758

760

761

745

In the case of the following flex studies, it is acceptable for you to provide documentation
indicating that flex studies have been conducted in accordance with a recognized industry
standard. We recommend you include the type of testing performed, the reference
standard followed, the acceptance criteria, and whether the SMBG device passed testing
requirements.

- The flex studies we recommend performing in this manner are:
 - Mechanical Vibration Testing
- 762 Shock Testing

Electromagnetic compatibility (EMC) Testing • 763 764 • Electrostatic Discharge/Electromagnetic Interference Testing 765 Unless otherwise indicated, we recommend that you clearly identify all flex studies 766 performed on your device in your premarket submission. A detailed description of the 767 following attributes should be included: 768 769 Study goal 770 • Study protocol and methods 771 • 772 • Methods used to apply samples to test strips Description of sample type and any anticoagulants used 773 • Study results 774 • Description of conclusions made from the study 775 • 776 We have also identified additional flex studies that we believe are important for 777 778 manufacturers to perform in order to demonstrate adequate system performance in 779 intended use settings. A list of these recommended flex studies as well as recommended study designs are included below. 780 781 1. Test Strip Stability Testing 782 You should perform a study to assess test strip performance throughout its claimed shelf 783 784 life. We request that you submit only the study protocol, the acceptance criteria for the 785 test strip stability study, and the conclusions of the study. 786 You should evaluate precision and accuracy of test strips at various time points 787 throughout their stated shelf life. You should indicate the time points that are assessed in 788 this stability protocol (e.g. 1 month, 3 months, 2 years); a combination of real-time and 789 accelerated aging studies are acceptable. You should perform both precision and 790 accuracy evaluations at each identified time point as described below. Through these 791 792 evaluations, you should demonstrate that the CV calculated in this study is within the 793 labeled performance of the SMBG device. 794 795 Precision Evaluation: 796 Precision with Control Materials This study should be completed over 5 days and use glucose controls. At least two 797 SMBG devices should be included in this study and at least 10 measurements should 798 be taken per control level per meter. 799 800 Precision with Whole Blood Samples 801 This study should be completed over 10 days using whole blood samples spanning the 802 SMBG device's stated measuring range. Samples may be altered by spiking with 803 glucose or allowing the samples to glycolyze in order to evaluate the extreme end of 804 the system's measuring range. At least two SMBG devices should be included in this 805 study and at least 10 measurements should be taken per glucose level, per meter. 806

807	
808	Accuracy Evaluation:
809	The study should be performed using patient whole blood samples that span the SMBG
810	device's stated measuring range. It is acceptable for samples to be spiked with a known
810	concentration of glucose, or allowed to glycolyze to achieve the desired concentration in
812	order to evaluate the extreme ends of the system's measuring range. Glucose
	concentrations should be measured on the SMBG meter and compared to values obtained
813	with the reference method.
814	with the reference method.
815	2 Town and How Hits Effects on SMDC Davis
816	2. <u>Temperature and Humidity Effects on SMBG Device</u>
817	We believe the following recommendation for conducting temperature and humidity
818	effects studies most closely represents actual use conditions experienced by users of OTC
819	SMBG devices.
820	
821	We recommend the simultaneous evaluation of temperature and humidity effects on
822	blood glucose meters and blood glucose test strips under "Open Vial" (i.e. to mimic use
823	of test strips after an individual user has opened a test strip vial) and "Extended Open
824	Vial" (i.e. to mimic use of test strips from vials that have been left completely open for
825	the duration of the claimed test strip vial shelf-life) conditions. Separate testing of test
826	strip and meter shipping and storage conditions are not necessary if, for these temperature
827	and humidity studies, only packaged blood glucose meters and blood glucose test strips
828	that have undergone appropriate storage conditions and the longest possible shipping
829	duration (both as specified by the manufacturer) are used. In addition, tested temperature
830	and humidity ranges should not only cover the claims specified in the device labeling, but
831	test conditions should also stress the SMBG device and include ranges outside of labeling
832	claims. We recommended that you test the effects of fluctuating temperate and humidity
833	on blood glucose meters and blood glucose test strip performance, as well as effects of
834	heat and humidity changes across the open vial shelf life. We recommend you use
835	multiple meters and test strip vials in these studies.
836	1 1
837	We recommend that you present results for temperature and humidity studies as the mean
838	values of measurements per meter. You should also include corresponding standard
839	deviations (SD) and coefficients of variation, as well as the grand mean, pooled variance,
840	pooled standard deviation (with 95% confidence intervals) and pooled CV. You should
841	describe your statistical methods. For statistical analysis, ANOVA is the preferred
842	method for calculating intermediate precision. You should also include a summary of any
843	identified outliers that were excluded from statistical analysis, the method of outlier
844	identification and the results of outlier investigations.
845	identification and the results of outlier investigations.
845 846	We encourage manufacturers to also consider ways in which temperature and/or humidity
840 847	detectors might be incorporated into test strip containers to alert users when strips have

detectors might be incorporated into test strip containers to alert users when strips have
not been handled correctly or stored according to recommended and validated conditions.

849 850

3. <u>Altitude Effects</u>

You should evaluate the effect of altitude on performance for your SMBG devices by 851 comparing results from whole blood samples with the candidate device to the reference 852 method. These studies should include a pressure change. Studies based on oxygen 853 tension instead of pressure change are not adequate, because oxygen tension is only one 854 component that changes with altitude. Altitude pressure changes can be accomplished by 855 physically increasing altitude (e.g., in an airplane, on a mountain), or by simulating 856 increasing altitudes and atmospheric conditions in a pressurized chamber. Results should 857 858 support the altitude labeling claim for your device. You should provide your definition for terms, such as "sea level". The definition of sea level should not extend past 500 feet. 859 You should test your SMBG device at a minimum of 10,000 feet above sea level. 860

861 862

4. Short Sample Detection

Blood glucose measurement from short samples (samples of reduced volume) can lead to
inaccurate results. To avoid the risk of inaccurate results, SMBG devices should be able
to detect that a short blood sample has been applied to the test strip and should not
provide a result to the user. Short sample detection systems should not rely on visual
verification by the user.

868

869 The volume required to classify a test sample as a short sample is dependent upon the SMBG device. In your short sample detection studies you should include blood samples 870 871 with known glucose concentrations in the following three ranges: 50-65 mg/dL, 100-120 mg/dL, and 200-250 mg/dL. You should test blood samples with your candidate SMBG 872 device at each of the glucose concentrations listed above. Blood samples with serially 873 reduced volumes should be measured on the device until an error is either generated by 874 the device or the test result falls outside of the device's stated performance range. Results 875 876 obtained from the candidate device should be compared to the reference method. In your submission you should describe the results from both the candidate device and the 877 reference method, as well as the sample volume tested for each of the tested glucose 878 concentration ranges. 879

880 881

5. <u>Sample Perturbation Study</u>

Sample perturbation occurs when a user has applied an appropriate volume of blood to
the test strip for glucose measurement but an event such as wicking of blood away from
the test strip, flicking of the test strip or flicking of the meter occurs during the start of
measurement and alters the volume of the initial sample application. Sample perturbation
often leads to a short sample.

887 888

You should adequately demonstrate how your SMBG handles sample perturbation,

through a sample perturbation study. In such a study, once a sample has been applied to the test strip and the SMBG device has begun to read the sample, the test strip should be

perturbed. The sample perturbation study should incorporate blood samples with known

glucose concentrations in the following three ranges: 50-65 mg/dL, 100-120 mg/dL, and

893 200-250 mg/dL. In your 510(k) submission you should describe your protocol, including

- vour specific method of perturbing the test sample, as well as meter results compared to 894 the reference method. 895
- 896 897

6. Intermittent Sampling

Intermittent sampling occurs when a short sample is applied to a test strip, a glucose 898 measurement begins, and the user adds more sample to the test strip before the glucose 899 900 measurement is complete.

901

You should adequately demonstrate how your SMBG handles intermittent sampling by 902 conducting a study. The intermittent sampling study should incorporate blood samples 903 with known glucose concentrations in the following three ranges: 50-65, 100-120, and 904 200-250 mg/dL. You should perform intermittent sampling studies that are representative 905 of actual events. For instance approximately one half of the sample should be applied to 906 907 the test strip prior to the start of sample measurement, then the other half of the sample should be applied to the strip once the sample starts reading. You should describe how 908 the device responds to this scenario, including whether a result is reported, whether this 909 result is accurate (relative to the reference method) and when an error code is reported. 910

911

7. Testing with Used Test Strips

912 We recommend that SMBG devices be designed to automatically recognize the insertion 913 of used test strips. Insertion of used test strips into a blood glucose meter should not 914 provide glucose measurement results to the user. If an automatic used test strip 915 916 recognition function has been incorporated into your SMBG device, you should perform a flex study to demonstrate the functionality of this recognition system. If an automatic 917 used test strip recognition function has not been incorporate into the design of the blood 918 919 glucose meter, you should submit flex study results demonstrating that the insertion of 920 used strips for glucose testing generates an appropriate error code to the user. In your 921 submission you should provide the study protocol, acceptance criteria and results. 922

F. Calibration and External Control Materials 923

924 The use of external control solutions allows consumers to periodically check the accuracy 925 of the SMBG device and test strip. In order to further promote the use of external control solutions by the user, you should include at least two levels of control materials to the 926 customer with each test strip vial. We recommend you follow FDA's "Guidance for 927 928 Industry and FDA Staff - Assaved and Unassaved Ouality Control Material" [http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument 929 s/ucm079179.htm] and submit the recommended information to support clearance of your 930

- assaved glucose quality control material. 931
- 932

933 Control solutions provided should not be labeled in a descriptive manner such as "low", "normal," or "high" since that may be misleading to the user. Users may confuse a label 934 that says "normal" as meaning that that is a clinically normal value even when the control 935 concentration is not within the normal range that is recommended by an individual user's 936

physician. Control solutions should be labeled non-descriptively (e.g., numerically - 1, 2, 3).
3).

For a description of more points to consider regarding calibration and quality control materials, please reference the guidance document "In Vitro Diagnostic Devices:

materials, please reference the guidance document "In Vitro Diagnostic Devices

Guidance for the Preparation of 510(k) Submissions – Appendix K – Points to Consider
 for Review of Calibration and Quality Control Labeling for In Vitro Diagnostic Devices"
 (http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument

- 945 <u>s/ucm094635.htm</u>).
- 946

You should describe how the candidate system recognizes and distinguishes calibration or
control materials from patient specimens as well as explain how the system compensates
for differences between strip lots or strip types.

950

951 VII. Test Strip Lot Release Criteria

952

Your test strip lot release criteria should be sufficient to ensure consistent performance of
your SMBG test strips. You should provide a description of the lot release criteria and a
summary of the sampling scheme in your premarket notification.

956

957 We recommend that you select a sampling scheme appropriate for the operation of your device and test each outgoing test strip lot or batch using the precision and accuracy 958 959 evaluations described below. Your release criteria should be designed to ensure that all released lots conform to the labeled SMBG device performance in the hands of the intended 960 *user*. Therefore, these criteria should be more stringent than the criteria used to evaluate total 961 error in the user studies. Estimates of the device's imprecision and average bias may be used 962 to determine appropriate criteria. For example, if the device has an average CV of 3% and an 963 average bias of 5%, these may be considered in determining the appropriate lot release 964 965 criteria.

- 966 967 *Precision Evaluation:*
- 968 Precision using Control Materials
- This study should be completed over 5 days and use glucose controls. At least two
 SMBG devices should be included in this study and at least 10 measurements should
 be taken per control level per meter.
- 973 <u>Precision using Whole Blood Samples</u>
- 974This study should be completed over 10 days using whole blood samples spanning975the SMBG device's stated measuring range. Spiking samples with glucose, or976including samples in which glucose was allowed to glycolyze is acceptable in order977to evaluate the extreme end of the system's measuring range. At least two SMBG978devices should be included in this study and at least 10 measurements should be979taken per glucose level, per meter.
- 980

981 Accuracy Evaluation:

The accuracy evaluation should be performed using patient whole blood samples that span the SMBG device's stated measuring range. It is acceptable for samples to be spiked with a

983 the SMBG device's stated measuring range. It is acceptable for samples to be spiked with a 984 known concentration of glucose, or to include samples in which the glucose was allowed to 985 glycolyze in order to evaluate the extreme ends of the system's measuring range. Glucose 986 concentrations should be measured on the SMBG meter and compared to the reference

- 987 method.
- 988

989 *Third Party Test Strips:*

990 Third party test strips refer to test strips manufactured and distributed by a company other than the company that manufactures and distributes the glucose meter. Third party strip 991 manufacturers should ensure that they are aware of any design changes to the meter, because 992 993 such changes could affect compatibility of the strip with the meter. We strongly recommend 994 that agreements between the third party strip manufacturer and the meter manufacturer are in 995 place to ensure that the third party strip manufacturer is made aware of any design changes to the meter. In cases where this is not possible, the third-party strip manufacturers should 996 sufficiently address, in their submission, how they will mitigate the risk of incorrect results 997 due to meter design changes. 998

999

1000 VIII. Software

1001

For software descriptions of SMBG devices, their components, and accessories, we
 recommend that you follow Guidance for the Content of Premarket Submissions for
 Software Contained in Medical Devices,

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument
 s/ucm089543.htm. Generally, FDA considers glucose meters to be a moderate level of
 concern because glucose results will be the basis for treatment, including determination of
 insulin dosage by the patient or health care provider. Incorrect glucose results or failure of
 the software to detect an error could result in improper diabetes management. (Also see
 Section VI, above regarding software descriptions in your 510(k)).

1011

1012 IX. Labeling

1013

The labeling of a SMBG includes a user manual, package inserts for both test strips and 1014 controls, and box and container labels for the meter, test strips, and control materials. The 1015 1016 package inserts for test strips and controls, and the user manual should be simple, concise. and easy to understand. Graphics such as line drawings, illustrations, icons, photographs, 1017 tables, and graphs are very useful tools. Manufacturers should ensure that the same terms are 1018 1019 used consistently throughout the labeling to identify the device and its parts, avoiding 1020 synonyms or alternate phrases. Symbols should not be used in the labeling of OTC devices. We recommend that you refer to the following documents for information on important 1021 1022 principles for developing clear and complete home use IVD labeling:

1023		
1025	Guidance on Medical Device Patient Labeling; Final Guidance for Industry an	h
1024	FDA (2001),	u
1025	http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocu	m
1020	ents/ucm070782.htm.	111
1028	Labeling of Home-Use In Vitro Testing Products; Approved Guideline, CLSI	
1029	GP-14 (1996).	
1030 1031 1032	• Device Advice website titled Labeling Requirements - In Vitro Diagnostic Devic [http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/Dev ceLabeling/InVitroDiagnosticDeviceLabelingRequirements/default.htm]	
1033 1034 1035 1036 1037 1038	Technical information, required by 21 CFR 809.10(b), should be described so that lay users can understand the information or locate it if necessary. Detailed technical information (e.g chemical details of test principle or statistical analyses of data) may be presented in a separa section followed by clarifying statements appropriate for lay users.	5.,
1038 1039 1040 1041 1042	The premarket notification must include labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). Final labeling must also satisfy the requirements of 21 CFR 809.10.	
1043 1044 1045	The following items are intended to further assist sponsors in complying with the requirements of 21 CFR 809.10 for test strip and meter labeling.	
1046 1047 1048 1049 1050	 The device container and package insert must contain the proprietary and common name of the device. 21 CFR 809.10(a)(1) and 21 CFR 809.10(b)(1). The various test system components should have the same name (ABC blood glucose test system, ABC blood glucose meter, ABC blood glucose test strips, etc.) to aid in identification of system components. 	
1051 1052 1053 1054	 You must include on the label and labeling the intended use of the product. 21 CFR 809.10(a)(2) and 21 CFR809.10(b)(2). The intended use for OTC SMBG devices shoul be similar to the example below: 	ld
1054 1055 1056 1057 1058 1059 1060	The XYZ Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in capillary whole blood from the finger. It is intended for use I people with diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. The XYZ Blood Glucose Monitoring System is intended to bused by a single person and should not be shared.	-
1060 1061 1062 1063 1064	 You must include warnings appropriate to the hazard presented by the product. (21 CFR 809.10(b)(5). You should include the following warning <i>prominently</i> on the outer box labeling and package insert. 	Ľ
1064 1065 1066	This device is not intended for use in healthcare or assisted-use settings such as hospitals, physician's offices, or long-term care facilities because it has not been	

		Druji - Noi jor implementation
1067		determined to be safe and effective for use in these settings, including for routine assisted testing or as part of glycemic control procedures.
1068		assisted testing of as part of gryceniic control procedures.
1069 1070		Use of this device on multiple patients may lead to transmission of Human
1070		Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV),
1071		or other bloodborne pathogens.
1072		of other bioouborne pathogens.
1073	4.	Labeling must include the chemical, physical, physiological, or biological principles of
1074	т.	the procedure (21 CFR 809.10(b)(4)). The discussion of these principles should include
1075		identification of the enzyme and description of the reaction. Labeling should specify
1070		whether results are determined in terms of whole blood or plasma equivalents. SMBG
1078		devices intended for use in the U.S. should report results in terms of plasma equivalents.
1079		actions internated for use in the C.S. Should report results in terms of plasma equivalents.
1080	5.	The label must include a means by which the user may be assured that reagents meet
1081	υ.	appropriate standards of identity, strength, quality and purity at the time of use.
1082		(809.10(a)(6)).
1083		
1084	6.	The labeling must provide instructions for specimen collection and preparation. (21 CFR
1085		809.10(b)(7)). Instructions should include a statement to users on the importance of
1086		thoroughly washing and drying the skin before taking a sample, because contaminants on
1087		the skin may affect results. See also instructions for cleaning and disinfection, below.
1088		
1089	7.	The labeling must provide a step-by-step outline of recommended procedures (21 CFR
1090		809.10(b)(8)), and operating instructions for the instrument (21 CFR 809.10(b)(6)(v)).
1091		Numbering, rather than bullets should be used for clarity when appropriate (e.g.
1092		procedural steps, etc.). You should include this information in the User Manual.
1093		
1094	8.	Labeling must include a statement of limitations of the procedure including known
1095		extrinsic factors or interfering substances affecting results (21 CFR 809.10(b)(10)). You
1096		should include testing conditions that may cause clinically significant errors (due to bias
1097		or imprecision) with your device (e.g., specific drugs, oxygen therapy, high altitude). You
1098		should indicate the most extreme conditions (e.g., the highest altitude) at which device
1099		should be used based on the results of performance testing.
1100	0	
1101	9.	You should clearly indicate to users what display they will expect to see when their
1102		measured glucose is lower or higher than the measuring range of the meter. For example,
1103		meter XYZ has a measuring range that goes down to 50 mg/dL. All glucose values
1104		measured below 50 mg/dL will provide the following error code: "Less than 50". Meter
1105		XYZ's labeling would include a statement explaining this error code: "When your
1106		glucose value is less than 50 mg/dL you will see the following error code 'Less than 50'".
1107	10	Laboling must describe details of colibration and of quality control procedures (21 CED
1108	10.	Labeling must describe details of calibration and of quality control procedures (21 CFR $\frac{809}{10(b)(8)(y)}$ and 21 CFR $\frac{809}{10(b)(8)(y)}$. This is to help ensure optimal
1109		809.10(b)(8)(v) and 21 CFR 809.10(b)(8)(vi)). This is to help ensure optimal performance of the system. This section should include recommendations for how and
1110		performance of the system. This section should include recommendations for how and when to perform quality control checks and instructions for what to do if the control
1111		when to perform quality control checks and instructions for what to do if the control

1112 material values are not within the manufacturer's allowable range. As part of the quality 1113 control information in your labeling, we recommend sponsors advise users that they 1114 should periodically review their technique and compare a result obtained with their meter 1115 to a result obtained using a laboratory method or a well-maintained and monitored system 1116 used by their healthcare provider.

- 1117
- 1118 11. Labeling must include expected values (21 CFR 809.10(b)(11)). FDA recommends that
 the expected values in the package insert should be those for non-diabetics. FDA does
 not recommend including additional ranges adjusted for diabetics because such ranges are
 individualized and determined by the clinician. The expected values should be cited from
 in-house studies or up-to-date reference sources.
- 1123
- 124 12. Labeling must include specific performance characteristics (21 CFR 809.10(b)(12)).
 125 Sponsors should briefly describe all studies and summarize results in the package inserts.
 126 FDA recommends that this include performance data summaries from in-house and user
 127 studies. For presentation of accuracy in particular, see the charts below for an example.
 128 Performance should be presented separately for each anatomical site and matrix.
- 1129
- 1130 Accuracy information:

So that home users have the ability to choose the SMBG device that is right for them, it is important to clearly describe the performance of the device in a way that is easy for them to understand. It is also important for this information to be located in a prominent place in product labeling so that lay users can understand the performance of an individual SMBG device both prior to purchase and also when they are learning to use the device they have purchased. Therefore, both the outer box labeling and the package insert should have easily understood depictions of the clinical study results.

1138

In the package insert for the test strips and the user manual for the SMBG device, accuracy information should be prominently and logically placed within the label. We recommend that this information be included in the section where the manual describes how a user will obtain a result. In the test strip insert, this section should be large and

- 1143 centrally placed so that users understand the performance of the system using these test
- strips. We recommend the following types of presentations to represent the results of
- 1145 your accuracy studies in the user manual and test strip inserts.
- 1146

Suggested Representation of Accuracy for Lay Users - Example

Your ABC Meter result may vary slightly from your actual blood glucose value. This may be due to slight differences in technique and the natural variation in the test technology.

The chart below shows the results of a study where 350 typical users used the ABC meter to test their blood glucose level. For example, in this study, the ABC meter gave results within 15% of their true blood glucose level 340 out of 350 times.

Difference range between the true blood	Within	Within	Within	Within
glucose level and the ABC meter result.	5 %	10 %	15 %	20%
The percent (and number) of meter results that	57%	94%	97%	100%
match true blood glucose level within x%	(200/350)	(330/350)	(340/350)	(350/350)

1147

Accuracy information should also be included on the SMBG device and test strip outer box

1149 labeling and test strip vials as well as in the package inserts and user manual. We

recommend that this outer box label accuracy information refer readers to the package insert

and graphically represent the user study data. An example of this type of presentation is

shown below. Numbers represent the number of meter results that were within the level of

accuracy shown, relative to the laboratory device.

1154

Accurate	350 out of 350
More Accurate	262 out of 350
Most Accurate	175 out of 350

1155 1156

Accuracy key	Percentages listed are meter values as compared to laboratory values
Accurate	+/-15%
More Accurate	+/-10%
Most Accurate	+/-5%

 1159 13 1160 1161 1162 1163 	You must describe the principles of operation for the instrument as well as service and maintenance information (21 CFR 809.10(b)(6)). Labeling should include a list or summary of error messages, descriptions of what those error messages mean, and appropriate troubleshooting procedures for those error messages.
	You should provide a working U.S. toll free telephone number for user assistance in the manual and package insert, and include hours of operation. If user assistance is not provided 24 hours/7 days a week/365 days a year, sponsors should provide instructions for what measures the user should take when user assistance is not available.
	The label and labeling must include statements of warning or precautions as appropriate to the hazard presented by the product (21 CFR 809.10(a)(4), (b)(5)(ii)). We recommend that you include instructions to lay users to contact their healthcare provider, if they obtain results that are not consistent with the way they feel, and to not change their medication regimen without approval from a healthcare provider. You should clearly <u>and prominently</u> state the important warnings for this device in the front of the label, in a section containing Important Safety Instructions. Important warnings and safety information should be included on all test system instructions (User manual, test strip labeling, etc.):
1179 1180 1181 1182	You should stress the risk of disease transmission when using SMBGs and reference any relevant public health notifications, standard practice guidelines, or other resources available to users. At a minimum, the following warnings should be included:
1182 1183 1184 1185 1186 1187	 The meter and lancing device are for single patient use. Do not share them with anyone including other family members! Do not use on multiple patients! All parts of the kit are considered biohazardous and can potentially transmit infectious diseases, even after you have performed cleaning and disinfection.
1187 1188 1189	You should include these references:
1190 1191 1192 1193 1194	"FDA Public Health Notification: Use of Fingerstick Devices on More than One Person Poses Risk for Transmitting Bloodborne Pathogens: Initial Communication" (2010) http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm224025.htm
1194 1195 1196 1197	CDC website on "Infection Prevention during Blood Glucose Monitoring and Insulin Administration", <u>http://www.cdc.gov/injectionsafety/blood-glucose-monitoring.html</u>
1197 1198 1199 1200 1201 1202 1202	In the section(s) describing how to obtain a blood sample , you should re-iterate the risk of bloodborne pathogen transmission. You should stress that a lancing device is intended only for a single user and should not be shared. You should stress that users should clean hands thoroughly with soap and water after handling the meter, lancing device, or test strips.

The user manual should contain detailed instructions for how and when users should 1204 perform cleaning and disinfection procedures for the meter and/or lancing devices, 1205 based on the validation studies performed. Specifically the instructions should include 1206 the following: 1207 1208 An explanation of why the cleaning and disinfection should be performed in • 1209 language that is appropriate for the intended user audience. You should explain 1210 the difference between "cleaning" and "disinfection." 1211 The recommended frequency. For example, the meter should be cleaned and 1212 • disinfected at a minimum of once per week. An explanation should be provided 1213 for how this number relates to the number of validated cycles over the life of the 1214 1215 device. The use life of the device should be clearly stated. 1216 • A list of the materials needed for cleaning and disinfection should be provided. Instructions on how these products can be purchased or prepared need to be 1217 1218 clearly outlined. A detailed procedure describing what parts of the device should be cleaned and 1219 • disinfected, the amount of time the cleaner or disinfectant needs to remain on the 1220 meter or lancing device (contact time), etc. You should include 1221 graphics/photographs to assist the user. 1222 • A statement that users should clean hands thoroughly with soap and water after 1223 handling the meter, lancing device, or test strips. 1224 A contact telephone number for technical assistance or questions should be 1225 • prominently listed in the cleaning and disinfection section along with a list of 1226 signs of external deterioration and deteriorating performance that the user should 1227 look for. 1228 1229 16. If studies have not been presented supporting the use of alternative site testing (AST) for 1230 a SMBG device, you should include a prominent warning in the labeling against use of 1231 1232 the device for AST. Sampling from anatomical sites other than the fingertip, i.e., 1233 forearm, upper arm, thigh, calf, palm, may be indicated for some SMBG devices. 1234 Some users may prefer obtaining blood from alternative sampling sites because of less 1235 pain or greater choice in puncture sites. However, studies have shown that during times 1236 of rapidly changing glucose (i.e., after meals, medication, or exercise), the glucose level 1237 1238 in blood from the alternative site may be significantly different from the glucose level 1239 from the finger. Additionally, glucose levels may not rise as high or fall as low as levels in the fingertip. This can result in a delay, or a failure to detect, hypoglycemia when 1240 1241 glucose is measured in alternative sites during non-fasting times. 1242 When alternative sampling sites have been validated, and are indicated, you should clarify 1243 that results from these sites may lag behind finger stick during periods of glucose change, 1244 or reduced peripheral circulation (e.g., shock). 1245

1247 If the AST studies conducted do not include any challenges evaluating rapid increases or decreases of glucose levels, you should include the following limitations in your package 1248 insert: 1249 1250 Alternative site results may be different from fingertip results when glucose levels 1251 • are changing rapidly (e.g., after a meal, after taking insulin, or during or after 1252 1253 exercise). • Do not rely on test results at an alternative sampling site, but use samples taken 1254 from the fingertip, if any of the following applies: 1255 you think your blood sugar is low. 1256 . you are not aware of symptoms when you become hypoglycemic. 1257 . the site results do not agree with the way you feel. . 1258 1259 . after a meal. 1260 . after exercise. . during illness. 1261 during times of stress. 1262 . 1263 • Do not use results from alternative site samples to calibrate continuous glucose 1264 1265 monitoring systems (CGMS), or for insulin dose calculations. 1266 1267 1268

1269

Appendix 1. Potential sources of error to consider for SMBG Devices

1272

The following table lists potential sources of error associated with the design, production, and use of SMBG devices. We do not intend for this to be a complete list. You should consider all sources of error based on your knowledge of your specific device. Documents such as CLSI EP-18A and ISO 14971 also provide lists of preanalytical, analytical, and postanalytical errors to consider.

Category	Source of error or failure
Operator	 Failure to follow procedure correctly, for example: Sample contamination Incorrect specimen collection (e.g., poor lancing technique and incorrect volume) Application of an insufficient amount of blood to the strip or incorrect application of blood to strip Use of a sample from an alternative site at inappropriate times or from a site not validated by the manufacturer Application of the specimen to the strip more than once (for example, if the user believes not enough specimen was added the first time) Incorrect insertion of strip into meter Inaccurate timing Use of contaminated, outdated, or damaged strips or reagents, including calibrators or quality control materials Failure to understand or respond to meter output. Errors in meter maintenance or cleaning Errors in calibration or failure to calibrate or otherwise adjust the meter or check performance with quality control materials, as directed by labeling Incorrect saving or use of stored data Improper storage or handling of the meter, calibrators, quality control materials or test strips, or maintenance of the meter Inadvertent changes of parameters (such as units of measurement) Failure to contact physician when necessary (OTC) Incorrect incorporation of results into overall treatment plan (professional use) Use of strips not validated for use on the monitor
Reagent	Expired strips or reagents

	 Damaged or contaminated strip Failure of strips, calibrators, or quality control materials to perform adequately Incorrect manufacturing; product fails to conform with specifications Incorrect dimensions of reagent strip Interference with chemical reaction on strip (e.g., reducing
	 substances) Inadequate design of container for strips or other reagents; failure to prevent deterioration; failure of desiccant used to keep strips dry
Environmental	 DEVICE EFFECTS Temperature Humidity Altitude; hyperbaric conditions Electromagnetic radiation Visible light; sunlight HUMAN FACTORS Lighting, glare off meter surfaces Distractions, visual and auditory Stressful conditions Limited manual dexterity
Software	 Confusing or obscure user prompts and feedback Incorrect mathematical algorithm Undetected or unrecognized signal errors Timing failure Incorrect storage of test results in memory, including matching result with correct patient or time of test Other software failures
Hardware	 Electronic failure Physical trauma or vibration Damage to the device from incorrect strip dimensional tolerances (third party manufacturer) Electrostatic discharge Electromagnetic/radiofrequency interference Battery reliability, lifetime, and replacement Component(s) failure Incorrectly manufactured

System	 Physical trauma or vibration Incorrect calibration/adjustment (between lots of strips) Calibration failure, interference, instability or use beyond the recommended period of stability. Labeling not geared to intended user. Meter or operation complexity not geared to intended user Inadequate training
Clinical	 Interference from endogenous substances. Severe conditions (e.g., dehydration, hypoxia, hyperglycemic-hyperosmolar state, hypotension or shock, ketoacidosis). Interference from other sugars (e.g., maltose intravenous solutions)

1281 Appendix 2. Special 510(k)s and SMBG Devices

1282

1283 What is a special 510(k) and how does it apply to your blood glucose meter submission?

A special 510(k) submission is an alternative to the traditional method of demonstrating
substantial equivalence for certain modifications that do not alter the intended use or
fundamental scientific technology of the device. For such modifications, the Agency believes
that the rigorous design control procedure requirements outlined in the Quality System
Regulation (QS reg) [See 21 CFR part 820] produce highly reliable results that can form, in
addition to the other 510(k) content requirements, a basis for the substantial equivalence
determination.

1291 As such, under the special 510(k) option, a manufacturer who is intending to modify his/her

1292 own legally marketed device will perform and present the risk analysis and the necessary

1293 verification and validation activities to demonstrate that the design outputs of the modified

- device meet the design input requirements. Once the manufacturer has ensured the
- 1295 satisfactory completion of this process, a "Special 510(k): Device Modification" may be
- submitted.
- 1297

1298 Eligibility for a Special 510(k)

To determine whether a modified SMBG device is eligible to be submitted as a special
510(k), you should consult the FDA Guidance Document entitled "The New 510(k) Paradigm
Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications

- 1302 Final Guidance" which can be found at:
- 1303 <u>www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080</u>
- 1304 <u>187.htm</u>. Sponsors should also consult the document "How to Prepare a Special 510(k)" at:
- 1305 <u>http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevi</u>
 1306 ce/PremarketSubmissions/PremarketNotification510k/ucm134573.htm
- 1307

As noted above, a special 510(k) is appropriate where the candidate device is a modification
of a sponsor's own legally marketed device, which would serve as the predicate for the
modified device. This usually means that the candidate device and predicate device are part
of the same device design file. The existence of *similarities* between the predicate device A
and candidate device B does not by itself necessarily mean that device B is a modification of
device A.

1314

FDA believes that to ensure the success of the Special 510(k) option, there should be a common understanding of the types of device modifications that may gain marketing clearance by this path. In this vein, it is critical that Industry and Agency staff can easily determine whether a modification is appropriate for submission as a Special 510(k). To optimize the chance that a Special 510(k) will be accepted for review, sponsors should evaluate each modification to ensure that the device modification does not: (1) affect the

intended use or (2) alter the fundamental scientific technology of the device.

1323	Based on FDA's experience with blood glucose meters, we can offer the following list of
1324	modifications that may or may not be eligible for review as a special 510(k). This list is not
1325	intended to be all-inclusive.
1326	Madifications that are generally aligible for a gracial 510(k).
1327 1328	Modifications that are generally eligible for a special 510(k):
1328	• Minor changes in user interface
	e e
1330 1331	• Addition of wired data transfer capability (e.g., adding the ability to transmit glucose results to a personal computer)
1332	• Change in memory capabilities (e.g., adding the ability to store additional results)
1333	• Elimination of strip coding requirements through a restriction of test strip lot release
1334	criteria
1335	• Addition of a voice (speaking) feature if the device is not intended for visually
1336	impaired users
1337	
1338	Modifications that are generally NOT eligible for a special 510(k):
1339	
1340	• Significant change in the sample volume applied to the glucose test strip
1341	• Addition of alternate sampling sites (e.g., adding the palm in addition to the fingertip)
1342	• Addition of sample matrices (e.g., adding venous blood in addition to capillary blood)
1343	• Change to the measuring algorithm used to calculate a glucose concentration
1344	• Change in enzyme used in the chemical reaction (e.g. from glucose dehydrogenase to
1345	glucose oxidase)
1346	• Use of a test strip cleared for meter A for use on separately cleared meter B
1347	• Any modification that affects the intended use of the device
1348	• Any change in fundamental scientific technology
1349	
1350	We recommend that you contact OIR to discuss any specific questions you have regarding
1351	your SMBG device's eligibility to be submitted as a special 510(k).
1352	